Results 101 to 110 of about 3,700,331 (307)

Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe. [PDF]

open access: yes, 2009
Contains fulltext : 80544.pdf (publisher's version ) (Closed ...
Choy, E.   +11 more
core   +1 more source

Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease‐Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients

open access: yesArthritis care & research, 2019
Multiple studies have shown seemingly unfavorable changes in lipid profiles associated with interleukin‐6 receptor (IL‐6R) antagonists and some other therapies for rheumatoid arthritis.
F. Xie   +4 more
semanticscholar   +1 more source

Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis

open access: yesЖурнал инфектологии
The presented review searched for articles in the databases PubMed, Web of Science, Scopus, Google Scholar, eLibrary (2002-2022) and assessed the immunogenicity of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in adult patients with ...
B. Ts. Batozhargalova   +6 more
doaj   +1 more source

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

open access: yesHealth Technology Assessment, 2011
Background: Rheumatoid arthritis (RA) is an inflammatory condition that typically causes a symmetrical chronic arthritis. Timely use of disease-modifying antirheumatic drugs (DMARDs) is an essential aspect of disease management, but many patients may not
K Malottki   +10 more
doaj   +1 more source

Disease-modifying antirheumatic drugs – Old and new: A brief overview

open access: yesClinical Dermatology Review, 2019
Rheumatological disorders comprise a vast subset of conditions with differing manifestations but overlap in pathogenesis. Disease-modifying antirheumatic drugs (DMARDs) are a diverse group of medications which aim at the various pathogenic factors ...
Vidya Divakar Baliga, Raghuveer S Prabhu
doaj   +1 more source

Zero-shot Learning of Drug Response Prediction for Preclinical Drug Screening [PDF]

open access: yesarXiv, 2023
Conventional deep learning methods typically employ supervised learning for drug response prediction (DRP). This entails dependence on labeled response data from drugs for model training. However, practical applications in the preclinical drug screening phase demand that DRP models predict responses for novel compounds, often with unknown drug ...
arxiv  

Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents. A systematic review of randomized controlled trials [PDF]

open access: yes, 2014
Objective. Treatment with tumour necrosis factor antagonists (anti-TNF) has been recognized as a risk factor for tuberculosis (TB) reactivation. Our aim was to evaluate risk of TB reactivation in rheumatologic and non-rheumatologic diseases treated with ...
Armuzzi, Alessandro   +9 more
core   +1 more source

Sarilumab and Nonbiologic Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

open access: yesArthritis & Rheumatology, 2016
To evaluate the efficacy and safety of sarilumab plus conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) in patients with active moderate‐to‐severe rheumatoid arthritis (RA) who had an inadequate response or intolerance to anti–tumor ...
R. Fleischmann   +9 more
semanticscholar   +1 more source

Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis [PDF]

open access: yes, 2019
Objective: To calculate the persistence, over a period of eight years, the retention rate of first and second-line of treatment with biological agents in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis and to compare ...
Balsa, Alejandro   +5 more
core   +3 more sources

Clinical connectivity map for drug repurposing: using laboratory tests to bridge drugs and diseases [PDF]

open access: yesarXiv, 2020
Drug repurposing has attracted increasing attention from both the pharmaceutical industry and the research community. Many existing computational drug repurposing methods rely on preclinical data (e.g., chemical structures, drug targets), resulting in translational problems for clinical trials.
arxiv  

Home - About - Disclaimer - Privacy